Duchenne/Becker muscular dystrophy (DMD/ BMD), the most common X-linked muscular dystrophy is caused by mutations in the enormously large DMD gene. We screened this gene in 51 unrelated Bulgarian DMD/BMD patients and four families with no living index patient available, by multiplex ligation-dependent probe amplification (MLPA) analysis, which is a powerful tool for detecting deletion/duplication along the DMD gene. This, in combination with direct sequencing, characterized the mutation in all patients, which comprised 42 deletions (82%), six duplications (12%) and three point mutations (6%), and precisely determined all deletion/duplication borders. In all the families with no living index patient available, deletions were detected by direct analysis on the patients' mothers and sisters, proving the value of MLPA for carrier status determination.
INTRODUCTION
Duchenne/Becker muscular dystrophy (DMD/ BMD; OMIM#310200; 300376), the most common X-linked muscular dystrophy, is caused by mutations in the enormously large DMD gene (2.4 Mb; 79 coding exons). About 60% of the cases are due to deletions of one or more exons, ~20% to duplications of one or more exons [1] , and in 10% to point mutations of different type and location [1] . So far, the deletions have been mainly screened on the hot-spot regions by standard multiplex polymerase chain reaction (mPCR) [2, 3] . Precise deletion borders have rarely been clarified by analysis of single exons, and then only for research rather than a diagnostic purpose [4, 5] .
Recently, MLPA (multiplex ligation-dependent probe amplification) analysis [6] was successfully applied in the study of the DMD gene and resolved many complications of routine diagnostic approaches that are offered to DMD/ BMD families.
MUTATIONS IN DMD/BMD PATIENTS
Although not yet approved for diagnostic purposes, MLPA has been broadly applied for analyzing different genes [6] . However, it has been accepted as a standard in analysis of DMD/BMD patients and in preparing them for future gene therapy, and is required for inclusion in the Treat-NMD Network [7] . Here we present our results and experience in use of MLPA/direct sequencing for molecular analysis of the DMD gene in Bulgaria.
MATERIALS AND METHODS
Patients. Fifty-one patients and four families with no living index patient available were analyzed by MLPA/ direct sequencing. All patients were diagnosed clinically only on the basis of clinical symptoms, family history, electromyography (EMG) data and creatine kinase levels. In some, the result of muscular biopsy was also available. Thirty-six patients were severely affected, diagnosed as DMD, 14 had BMD and one patient was considered to represent an intermediate form (IMD). The affected members of the four families with no living index patient were suspected to be severely affected (there was one affected patient in each family).
Method. DNA samples were obtained from peripheral blood, using a DNA extraction kit (QIAamp DNA Mini Kit, QIAGEN, Hilden, Germany). Multiplex PCR of 18 exons for deletions detection along the deletion hot-spot was performed by the classical protocols of Chamberlain et al. [2] and Beggs et al. [3] .
The SALSA MLPA P034/P035 (MRC-Holland, Amsterdam, The Netherlands) kit was used in accordance with the manufacturer's instructions [6] . Fifty to 200 ng of DNA were diluted with TE (Tris/ EDTA) (1 M Tris, 0.5M EDTA, pH 8.0) buffer to a volume of 5 mL. The diluted samples were subjected to hybridization with the DMD gene-specific probes for all 79 exons and to 13 control probes (along Y, Xq and Xp chromosome regions) situated in both sets P034 and P035 [6] , at 60°C overnight. The hybridized probes were ligated with a specific ligase mix, provided by the manufacturer. The final step represents PCR amplification of the ligated fragment products. The PCR buffer, PCR primers 6-FAM (6-carboxyfluorescein) labeled, the enzyme dilution buffer and the polymerase were provided in the kit.
The PCR products obtained were analyzed on an ABI PRISM™ 310 genetic analyzer (Applied Biosystems, Foster City, CA, USA) in the presence of ROX500 size standard (Applied Biosystems). Each patient sample was analyzed simultaneously with at least two normal male samples. In order to assess copy number changes (duplications) in comparison to the normal controls, MLPA data interpretation was performed by MLPA software -Coffalyser [6] .
Sequencing. The DNA from patients who tested negative by MLPA were sequenced for the entire coding sequence of the DMD gene, including exon/ intron borders. Each exon was amplified by primers, designed for sequencing in our laboratory (the primer sequence is available upon request). The PCR product was purified by PCR Product Pre-Sequencing Kit [United States Biochemicals (USB); Affymetryx Inc., Santa Clara, CA, USA] and sequenced by the BigDye Terminator Cycle Sequencing Kit v.3.1 (Applied Biosystems). The sequenced sample were subjected to a standard ethanol precipitation. The pellet was air-dried and kept at room temperature in the dark. Before run, the pellet was resuspended in 13 mL Hi-Di Formamide (Applied Biosystems) and loaded into the ABI PRISM™ 310 genetic analyzer (Applied Biosystems). Sequencing results were interpreted by Sequence Scanner v.1 (Applied Biosystems).
RESULTS AND DISCUSSION
The mutations we detected and clinical data are listed in Tables 1a and 1b . Some of these patients were reported in our previous paper [8] . The creatine kinase levels were highly elevated in all cases, with the exception of creatine kinase levels in handicapped patients, where the destroyed muscle leads to creatine kinase level normalization. The main group of patients started walking later than normal children (after 12 months). In two cases: deletion patient #32 and duplication patient #2, a serious delay in starting to walk was registered at around or after second year of age. The duplication patient #2 had very severe symptoms with an early involvement of limbs, limb-girdle and neck muscles and fast disease progression.
The early symptoms in all patients have been very similar: walking on toes, difficulties in climbing stairs, running, getting up. Family history (the presence of other affected family members) was positive in 13 cases. The deletion patient #23 had been clinically diagnosed as Emery-Dreifuss muscular dystrophy (OMIM#181350; OMIM#310300). The precise diagnosis of BMD was established during the present study.
Of interest is the deletion of the very last exon of the DMD gene (exon 79), detected in deletion patient #6. It is not clear where the deletion ends, but the clinical picture was compatible with DMD phenotype (early onset and fast progression). Deletion patient #29 also had a deletion covering exon 79. He was also severely affected with a fast disease progression. A similar mutation has been described earlier in a BMD patient as a part of a contiguous gene deletion syndrome [9] .
Two duplications of exons 2-33 and 13-40 (duplication patients #2 and #4) cover more than onethird of the gene sequence, and result in DMD and BMD phenotypes, respectively. Most probably, the duplication situated close to the N-terminus of the dystrophin is associated with a severe phenotype, while the one in the rod-domain leads to the BMD phenotype [8] .
Some patients were pre-screened for deletions in the DMD gene by a standard multiplex set of primers. In deletion patient #14 the deletion of exons 49-50 was detected in this way, but the family requested confirmation with an alternative method. In several cases the deletions were detected by mPCR, but deletion borders were not precisely determined, or carrier status determination in these families required MLPA. In deletion patients #37 and #39, the deletion of exon 44 was not detected by multiplex PCR (most probably because of PCR unspecificity or contamination) and they were not considered as deletions. A number of index patients were classified as unknown mutations after mPCR.
The MLPA analysis/direct sequencing charac- Table 1 continue terized mutation in all cases, which comprised 42 deletions (82%), six duplications (12%) and three point mutations (6%) (see Table 1a ). In addition, this analysis in the four families with no living index patient revealed deletions in all families of dead patients diagnosed with DMD, using the DNA samples of their mothers and sisters (see Table 1b ). All deletion/duplication borders were precisely determined by this method as required for adequate gene therapy in the future. The deletion and duplication electrophoretic profiles are presented on Figure  1a and 1b. All deletions were confirmed by PCR amplification.
In our hands, the combination of the MLPA test with direct sequencing of the entire DMD gene, proved to be a powerful diagnostic approach in DMD/BMD families. In point mutation patient #2 only exon 23 was missing on the MLPA electropherogram. The single amplification of exon 23 showed its presence in the patient, but the point mutation c.2991C>G, p.Tyr997X was detected by sequencing of the exon [8] . Point mutation patients #1 and #3 tested negative by MLPA, but sequencing of the entire coding sequence of the DMD gene revealed the nonsense mutations c.8776C>T, p.Gln2926X and c.583C>T, p.Arg195X, respectively [8] .
The classical mPCR of 18 exons in the deletion hot-spot region of the DMD gene [2, 3] could detect 36 deletions in the present sample (86% of deletions), 15 of which (42%) were only partial, with no clear deletion borders. The mPCR could only detect deletions, and it is applicable only when the index patient is available for study. Moreover, the presented MLPA analysis was successful not only in all the patients tested, but also in all four families with no index patient. We identified four deletions in these families (see Table 1b ); all four mothers were deletion carriers, one sister was genetically proved to be a carrier and two were not carriers. The MLPA data is easily interpreted also for direct carrier status determination.
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The application of the most recent genetic tests in our routine diagnostic studies, gave us the possibility to genetically clarify a number of Bulgarian DMD/BMD patients. A national web site for clinically and genetically well described neuromuscular cases is available [10] , according to the requirements of the Treat-NMD Network.
